Systemische Therapie von prämenopausalen Patientinnen mit hormonrezeptorpositivem, HER2-negativem Brustkrebs in den Frühstadien – Kontroversen und Standards in der Krankenversorgung

Zusammenfassung Die adjuvante endokrine Behandlung von prämenopausalen Patientinnen mit einem hormonrezeptorpositiven, HER2-negativen (HR-pos./HER2-neg.) Mammakarzinom unterliegt bei bestehender Ovarialfunktion einigen Besonderheiten. Als therapeutische Optionen stehen Tamoxifen mit oder ohne GnRH-Analogon und Aromatasehemmer mit GnRH-Analogon zur Verfügung. Des Weiteren wird die Ovarialfunktion durch eine vorherige Chemotherapie beeinflusst. Sowohl die Indikation für GnRH-Analoga in Kombination mit Tamoxifen als auch die Indikation für Aromatasehemmer (+GnRH-Analoga) sind für Patientinnen mit einem erhöhten Rückfallrisiko vorgesehen. In nationalen und internationalen Leitlinien und Therapieempfehlungen ist jedoch keine klare Grenze für ein mittleres oder hohes Risiko definiert, sodass viele Therapieentscheidungen für jede Patientin individuell getroffen werden. Dies spiegelt sich auch in einer großen nationalen und internationalen Variabilität z. B. beim Einsatz von Aromatasehemmern + GnRH-Analoga wider. Diese Übersichtsarbeit fasst die Datenlage zu den abgeschlossenen Studien (z. B. SOFT, TEXT, EBCTCG-Metaanalysen), den aktuellen Multigentest-Studien (TailorX, RxPonder, ADAPT) zusammen, diskutiert die Rationale für aktuell durchgeführte Studien (z. B. CLEAR-B) und gibt einen Ausblick auf künftige Fragestellungen.

[1]  J. Olson,et al.  Abstract GS1-05: Trial Assigning Individualized Options for Treatment (TAILORx): An Update Including 12-Year Event Rates , 2023, Cancer Research.

[2]  P. Francis Role of Ovarian Suppression in Early Premenopausal Breast Cancer. , 2023, Hematology/oncology clinics of North America.

[3]  M. Lux,et al.  Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer , 2022, Geburtshilfe und Frauenheilkunde.

[4]  F. Petraglia,et al.  Hormonal drugs for the treatment of endometriosis. , 2022, Current opinion in pharmacology.

[5]  M. Lux,et al.  Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer , 2022, Geburtshilfe und Frauenheilkunde.

[6]  M. Lux,et al.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2022 , 2022, Breast Care.

[7]  S. Shak,et al.  Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2– Early Breast Cancer , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  E. Winer,et al.  Abstract GS2-05: Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials , 2022, Cancer Research.

[9]  J. Bergh,et al.  Abstract GS2-04: Aromatase inhibitors versus tamoxifen in pre-menopausal women with estrogen receptor positive early stage breast cancer treated with ovarian suppression: A patient level meta-analysis of 7,030 women in four randomised trials , 2022, Cancer Research.

[10]  J. Cuzick,et al.  Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials , 2022, The Lancet. Oncology.

[11]  G. Hortobagyi,et al.  21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. , 2021, The New England journal of medicine.

[12]  P. Fasching,et al.  Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Yen-Shen Lu,et al.  Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women , 2021, Frontiers in Oncology.

[14]  E. Tokunaga,et al.  153P Adjuvant endocrine therapy combined with abemaciclib in monarchE patients with high-risk early breast cancer: Disease characteristics and endocrine therapy choice by menopausal status , 2021, Annals of Oncology.

[15]  A. Lluch,et al.  Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective , 2021, International journal of molecular sciences.

[16]  M. Lux,et al.  AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2021 , 2021, Breast Care.

[17]  M. Lux,et al.  Mutations in BRCA1/2 and Other Panel Genes in Patients With Metastatic Breast Cancer —Association With Patient and Disease Characteristics and Effect on Prognosis , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Glas,et al.  70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. , 2021, The Lancet. Oncology.

[19]  P. Francis,et al.  Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. , 2021, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[20]  P. Neven,et al.  Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  T. Rachner,et al.  Challenges in preventing bone loss induced by aromatase inhibitors. , 2020, The Journal of clinical endocrinology and metabolism.

[22]  Shagufta,et al.  Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer. , 2020, RSC medicinal chemistry.

[23]  Novartis , 2020, Definitions.

[24]  S. Michiels,et al.  Differential impact of endocrine therapy and chemotherapy on quality of life of breast cancer survivors: a prospective patient-reported outcomes analysis. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  M. Lux,et al.  Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients , 2019, International journal of cancer.

[26]  Troy R. E. Paddock Germany , 2019, Contesting the Origins of the First World War.

[27]  A. Guerrero-Zotano,et al.  Phase III evaluating the addition of fulvestrant (F) to anastrozole (A) as adjuvant therapy in postmenopausal women with hormone receptor-positive HER2-negative (HR+/HER2−) early breast cancer (EBC): results from the GEICAM/2006–10 study , 2019, Breast Cancer Research and Treatment.

[28]  P. Fasching,et al.  NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). , 2019, Journal of Clinical Oncology.

[29]  J. Olson,et al.  Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx. , 2019, Journal of Clinical Oncology.

[30]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[31]  M. Rezai,et al.  Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study. , 2018, European journal of cancer.

[32]  A. Meindl,et al.  Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history , 2018, BMC Cancer.

[33]  P. Francis,et al.  Premenopausal women with early breast cancer treated with estradiol suppression have severely deteriorated bone microstructure. , 2017, Bone.

[34]  M. Dowsett,et al.  Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. , 2017, The oncologist.

[35]  R. Gelber,et al.  Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  P. Neven,et al.  The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients , 2016, British Journal of Cancer.

[37]  P. Neven,et al.  Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Papish,et al.  Incidence and Predictive Factors for Recovery of Ovarian Function in Amenorrheic Women in Their 40s Treated With Letrozole. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[40]  J. Olson,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[41]  J. Forbes,et al.  Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials , 2015, The Lancet.

[42]  R. Gelber,et al.  Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. , 2015, The Lancet. Oncology.

[43]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[44]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  M. Climent,et al.  Incidence and predictors of ovarian function recovery (OFR) in breast cancer (BC) patients with chemotherapy-induced amenorrhea (CIA) who switched from tamoxifen to exemestane. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[46]  M. Gnant,et al.  Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. , 2012, European journal of cancer.

[47]  L. Collins,et al.  Pathologic features and molecular phenotype by patient age in a large cohort of young women with breast cancer , 2012, Breast Cancer Research and Treatment.

[48]  C. Madeddu,et al.  Obesity, Inflammation, and Postmenopausal Breast Cancer: Therapeutic Implications , 2011, TheScientificWorldJournal.

[49]  J. Griggs,et al.  American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  N Harbeck,et al.  PREPARE trial: a randomized phase III trial comparing preoperative, dose-dense, dose-intensified chemotherapy with epirubicin, paclitaxel, and CMF versus a standard-dosed epirubicin-cyclophosphamide followed by paclitaxel with or without darbepoetin alfa in primary breast cancer--outcome on prognosi , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  R. Gelber,et al.  Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[52]  N. Wolmark,et al.  Amenorrhea from breast cancer therapy--not a matter of dose. , 2010, The New England journal of medicine.

[53]  E. Perez,et al.  Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. , 2010, The New England journal of medicine.

[54]  R. Gelber,et al.  Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[55]  R. Greil,et al.  Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. , 2008, The Lancet. Oncology.

[56]  R. Gelber,et al.  Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[57]  W. Han,et al.  Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  S. Swain,et al.  Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  P. Lønning,et al.  Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  R. Gelber,et al.  Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  S. Singletary,et al.  Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  J. Forbes,et al.  A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. , 2005, The New England journal of medicine.

[63]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[64]  P. Lønning,et al.  Cognitive ability in childhood and cognitive decline in mid-life: longitudinal birth cohort study , 2003, BMJ : British Medical Journal.

[65]  R. Gelber,et al.  Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Cuzick,et al.  Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  A. Howell,et al.  Tamoxifen ("Nolvadex"): a review. , 2002, Cancer treatment reviews.

[68]  J. Cuzick,et al.  Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial , 2002, The Lancet.

[69]  R. Gray,et al.  Adjuvant therapy for very young women with breast cancer: need for tailored treatments. , 2001, Journal of the National Cancer Institute. Monographs.

[70]  J R Marshall,et al.  Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. , 2000, American journal of epidemiology.

[71]  R. Gelber,et al.  Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer? , 2000, The Lancet.

[72]  P. Goodwin,et al.  Risk of menopause during the first year after breast cancer diagnosis. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[73]  F. Cavalli,et al.  Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. , 1998, European journal of cancer.

[74]  R. Collins,et al.  Ovarian ablation in early breast cancer: overview of the randomised trials , 1996, The Lancet.

[75]  H. Adami,et al.  Transient increase in the risk of breast cancer after giving birth. , 1994, The New England journal of medicine.

[76]  R. Santen Recent progress in development of aromatase inhibitors , 1990, The Journal of Steroid Biochemistry and Molecular Biology.

[77]  G. Bonadonna,et al.  Combination chemotherapy as an adjuvant treatment in operable breast cancer. , 1976, The New England journal of medicine.

[78]  G. Beatson On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[79]  M. Rezai,et al.  Influence of patient and tumor characteristics on early therapy persistence with letrozole in postmenopausal women with early breast cancer: results of the prospective Evaluate-TM study with 3941 patients , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[80]  P. Fasching,et al.  Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials , 2010, Breast Cancer Research and Treatment.

[81]  Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992, Lancet.

[82]  Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. , 1992, Lancet.